These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23173973)

  • 1. Insulin resistance: a risk marker for disease and disability in the older person.
    Krentz AJ; Viljoen A; Sinclair A
    Diabet Med; 2013 May; 30(5):535-48. PubMed ID: 23173973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of C-reactive protein with body fat, diabetes and coronary artery disease in Asian Indians: the Chennai Urban Rural Epidemiology Study (CURES-6).
    Mohan V; Deepa R; Velmurugan K; Premalatha G
    Diabet Med; 2005 Jul; 22(7):863-70. PubMed ID: 15975100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body mass index correlates with ischemic heart disease and albuminuria in long-standing type 2 diabetes.
    Wentworth JM; Fourlanos S; Colman PG
    Diabetes Res Clin Pract; 2012 Jul; 97(1):57-62. PubMed ID: 22444424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Insulin resistance and cardiovascular complications].
    Janka HU
    Wien Klin Wochenschr; 1994; 106(24):758-62. PubMed ID: 7846894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular manifestations of insulin resistance.
    Chahwala V; Arora R
    Am J Ther; 2009; 16(5):e14-28. PubMed ID: 19114874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones.
    Nesto R
    Diabet Med; 2004 Aug; 21(8):810-7. PubMed ID: 15270782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium.
    Nathanson D; Nyström T
    Mol Cell Endocrinol; 2009 Jan; 297(1-2):112-26. PubMed ID: 19038307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diabetes, insulin, insulin analogues, and cancer].
    Müssig K; Staiger H; Kantartzis K; Fritsche A; Kanz L; Häring HU
    Dtsch Med Wochenschr; 2010 May; 135(18):924-9. PubMed ID: 20425680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body fat mass distribution. Influence on metabolic and atherosclerotic parameters in non-insulin dependent diabetics and obese subjects with and without impaired glucose tolerance. Influence of weight reduction.
    Van Gaal L
    Verh K Acad Geneeskd Belg; 1989; 51(1):47-80. PubMed ID: 2800685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of adiposity to subclinical atherosclerosis in obese patients with type 2 diabetes.
    Hegazi RA; Sutton-Tyrrell K; Evans RW; Kuller LH; Belle S; Yamamoto M; Edmundowicz D; Kelley DE
    Obes Res; 2003 Dec; 11(12):1597-605. PubMed ID: 14694226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes.
    Lautamäki R; Borra R; Iozzo P; Komu M; Lehtimäki T; Salmi M; Jalkanen S; Airaksinen KE; Knuuti J; Parkkola R; Nuutila P
    Am J Physiol Endocrinol Metab; 2006 Aug; 291(2):E282-90. PubMed ID: 16478772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes in old age: an emerging epidemic.
    Kesavadev JD; Short KR; Nair KS
    J Assoc Physicians India; 2003 Nov; 51():1083-94. PubMed ID: 15260395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiazolidinediones, insulin resistance and obesity: Finding a balance.
    Wilding J
    Int J Clin Pract; 2006 Oct; 60(10):1272-80. PubMed ID: 16981971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study.
    Solini A; Penno G; Bonora E; Fondelli C; Orsi E; Trevisan R; Vedovato M; Cavalot F; Cignarelli M; Morano S; Ferrannini E; Pugliese G;
    J Am Geriatr Soc; 2013 Aug; 61(8):1253-61. PubMed ID: 23889588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosiglitazone: potential beneficial impact on cardiovascular disease.
    Viberti GC
    Int J Clin Pract; 2003 Mar; 57(2):128-34. PubMed ID: 12661797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of cardiovascular disease in type 2 diabetes.
    Serrano Rios M
    Int J Clin Pract Suppl; 2001 Sep; (121):4-7. PubMed ID: 11594245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin resistance in the brain: an old-age or new-age problem?
    Williamson R; McNeilly A; Sutherland C
    Biochem Pharmacol; 2012 Sep; 84(6):737-45. PubMed ID: 22634336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adiponectin and E-selectin concentrations in relation to inflammation in obese type 2 diabetic patients with coronary heart disease(s).
    El-Mesallamy HO; Hamdy NM; Salman TM; Mahmoud S
    Minerva Endocrinol; 2011 Sep; 36(3):163-70. PubMed ID: 22019747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-resistance syndrome and cardiovascular complications of non-insulin-dependent diabetes mellitus.
    Fontbonne A
    Diabetes Metab; 1996 Oct; 22(5):305-13. PubMed ID: 8896991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obesity, type 2 diabetes and risk of digestive cancer.
    Hillon P; Guiu B; Vincent J; Petit JM
    Gastroenterol Clin Biol; 2010 Oct; 34(10):529-33. PubMed ID: 20864282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.